Article Type
Changed
Tue, 02/07/2023 - 16:39

Key clinical point: In patients with psoriatic arthritis (PsA), serum interleukin-23 (IL-23) levels were elevated and significantly correlated with disease activity (DA), depression, and anxiety.

Major finding: Serum IL-23 levels were higher in patients with PsA vs healthy volunteers without PsA (225.19 vs 118.12 pg/mL; P < .0001), and a significantly higher proportion of patients vs volunteers reported anxiety (45% vs 20%) and depression (35% vs 15%; both P < .0001). Serum IL-23 levels were positively correlated with Disease Activity Index for Psoriatic Arthritis (correlation coefficient [r] 0.959), Hospital Anxiety and Depression Scale (HADS) anxiety (r 0.932), and HADS depression (r 0.934; all P  =  .0001) scores.

Study details: Findings are from an observational case-control study including 80 patients with PsA and 80 matched healthy volunteers.

Disclosures: This study was funded by The Science, Technology & Innovation Funding Authority, Egypt, in cooperation with The Egyptian Knowledge Bank. The authors declared no conflicts of interest.

Source: Tabra SA et al. Serum interleukin-23 levels: Relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clin Rheumatol. 2022 (Jul 21). Doi: 10.1007/s10067-022-06300-1

Publications
Topics
Sections

Key clinical point: In patients with psoriatic arthritis (PsA), serum interleukin-23 (IL-23) levels were elevated and significantly correlated with disease activity (DA), depression, and anxiety.

Major finding: Serum IL-23 levels were higher in patients with PsA vs healthy volunteers without PsA (225.19 vs 118.12 pg/mL; P < .0001), and a significantly higher proportion of patients vs volunteers reported anxiety (45% vs 20%) and depression (35% vs 15%; both P < .0001). Serum IL-23 levels were positively correlated with Disease Activity Index for Psoriatic Arthritis (correlation coefficient [r] 0.959), Hospital Anxiety and Depression Scale (HADS) anxiety (r 0.932), and HADS depression (r 0.934; all P  =  .0001) scores.

Study details: Findings are from an observational case-control study including 80 patients with PsA and 80 matched healthy volunteers.

Disclosures: This study was funded by The Science, Technology & Innovation Funding Authority, Egypt, in cooperation with The Egyptian Knowledge Bank. The authors declared no conflicts of interest.

Source: Tabra SA et al. Serum interleukin-23 levels: Relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clin Rheumatol. 2022 (Jul 21). Doi: 10.1007/s10067-022-06300-1

Key clinical point: In patients with psoriatic arthritis (PsA), serum interleukin-23 (IL-23) levels were elevated and significantly correlated with disease activity (DA), depression, and anxiety.

Major finding: Serum IL-23 levels were higher in patients with PsA vs healthy volunteers without PsA (225.19 vs 118.12 pg/mL; P < .0001), and a significantly higher proportion of patients vs volunteers reported anxiety (45% vs 20%) and depression (35% vs 15%; both P < .0001). Serum IL-23 levels were positively correlated with Disease Activity Index for Psoriatic Arthritis (correlation coefficient [r] 0.959), Hospital Anxiety and Depression Scale (HADS) anxiety (r 0.932), and HADS depression (r 0.934; all P  =  .0001) scores.

Study details: Findings are from an observational case-control study including 80 patients with PsA and 80 matched healthy volunteers.

Disclosures: This study was funded by The Science, Technology & Innovation Funding Authority, Egypt, in cooperation with The Egyptian Knowledge Bank. The authors declared no conflicts of interest.

Source: Tabra SA et al. Serum interleukin-23 levels: Relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clin Rheumatol. 2022 (Jul 21). Doi: 10.1007/s10067-022-06300-1

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: PsA, September 2022
Gate On Date
Wed, 06/22/2022 - 10:45
Un-Gate On Date
Wed, 06/22/2022 - 10:45
Use ProPublica
CFC Schedule Remove Status
Wed, 06/22/2022 - 10:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
333554.27
Activity ID
83192
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
SKYRIZI [ 5052 ]